Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Joshua Kashanirokh

Rheumatology North Hollywood, CA Physician Assistant

NPI 1003562232 CMS profile 11309836

12922 Victory Blvd, North Hollywood, CA 91606

Open in the dashboard

General payments

$12,769

592 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joshua Kashanirokh of North Hollywood, CA is reported in the CMS Open Payments database as having received $12,769 across 592 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,719 215
2024 General $5,020 230
2023 General $2,477 123
2022 General $553 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joshua Kashanirokh
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Joshua Kashanirokh were reported at $4,719. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Joshua Kashanirokh Rheumatology median Middle half National median
2019 $0 $744 $153–$2,687 $163
2020 $0 $462 $98–$2,027 $114
2021 $0 $531 $101–$2,153 $132
2022 $553 $627 $125–$2,303 $149
2023 $2,477 $741 $145–$2,524 $160
2024 $5,020 $830 $166–$2,660 $164
2025 $4,719 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $2,682 148 payments
  2. Amgen Inc. $2,431 132 payments
  3. GlaxoSmithKline, LLC. $1,284 63 payments
  4. Janssen Biotech, Inc. $1,211 40 payments
  5. Mallinckrodt Hospital Products Inc. $847 33 payments
  6. AstraZeneca Pharmaceuticals LP $684 29 payments
  7. UCB, Inc. $629 28 payments
  8. Lilly USA, LLC $594 23 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $509 17 payments
  10. Pfizer Inc. $179 8 payments
  11. Other $1,718 71 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $12,246 586 payments
  2. Education $523 6 payments
Products named General payments · program years 2022–2025
  1. RINVOQ $1,834 83 payments
  2. TREMFYA $1,211 40 payments
  3. Enbrel $1,158 63 payments
  4. BENLYSTA $1,082 54 payments
  5. ACTHAR $847 33 payments
  6. Otezla $734 39 payments
  7. TALTZ $573 22 payments
  8. EVENITY $452 19 payments
  9. ZEPBOUND $406 14 payments
  10. OFEV $377 12 payments
  11. Other $5,733 289 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

592 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record